Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Total Current Liabilities (2019 - 2025)

Historic Total Current Liabilities for Legend Biotech (LEGN) over the last 7 years, with Q3 2025 value amounting to $433.6 million.

  • Legend Biotech's Total Current Liabilities rose 6005.23% to $433.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $433.6 million, marking a year-over-year increase of 6005.23%. This contributed to the annual value of $277.6 million for FY2024, which is 2829.11% up from last year.
  • Per Legend Biotech's latest filing, its Total Current Liabilities stood at $433.6 million for Q3 2025, which was up 6005.23% from $265.5 million recorded in Q2 2025.
  • In the past 5 years, Legend Biotech's Total Current Liabilities ranged from a high of $433.6 million in Q3 2025 and a low of $145942.0 during Q1 2021
  • For the 5-year period, Legend Biotech's Total Current Liabilities averaged around $228.6 million, with its median value being $238.2 million (2023).
  • Its Total Current Liabilities has fluctuated over the past 5 years, first soared by 22283113.78% in 2021, then crashed by 2732.48% in 2023.
  • Quarter analysis of 5 years shows Legend Biotech's Total Current Liabilities stood at $229.2 million in 2021, then grew by 29.92% to $297.8 million in 2022, then fell by 27.32% to $216.4 million in 2023, then grew by 28.29% to $277.6 million in 2024, then soared by 56.16% to $433.6 million in 2025.
  • Its last three reported values are $433.6 million in Q3 2025, $265.5 million for Q2 2025, and $234.4 million during Q1 2025.